Trial Profile
A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Cytokine release syndrome
- Focus Therapeutic Use
- Acronyms TACOS
- 16 Mar 2020 New trial record